Johnson & Johnson: stocks, financial statements

Disable ads for free
Dividends News

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

  • JNJ Ticker
  • NYSE Exchange
  • 135,100 Employees
36 rated
  • $149.00, +$0.86 (+0.58%) Previous Close
  • 7,301,329 Previous Volume
  • $108.89 / $152.77 52 week low / high
  • -3.03% Percent off 52 week high
  • 2020-12-03 Updated
  • 2.66% Dividend Yield (trailing)
  • 2.74% Dividend Yield (forward)
  • 0 Public float
  • 2,632,542,672 Outstanding shares
  • 22.96 P/E
  • 389.98 B Market Cap
Disable ads for free

Financial statements — Johnson & Johnson

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
82B 82B 76B 72B 70B
Cost Of Revenue
27B 27B 25B 22B 22B
Gross Profit
55B 54B 51B 50B 49B
Research and Development
11B 11B 10B 9B 9.1B
Selling General and Admin
22B 23B 21B 20B 21B
Operating Expense
61B 60B 57B 51B 52B
Operating Income
22B 21B 20B 21B 18B
Other Income Expense Net
-4.2B -3.3B -1.9B -1.5B 830M
22B 21B 20B 21B 18B
Interest Income
770M 1.2B 1B 760M 550M
Pretax Income
17B 18B 18B 20B 19B
Income Tax
2.2B 2.7B 16B 3.3B 3.8B
Minority Interest
0 0 0 0 0
Net Income
15B 15B 1.3B 17B 15B
Net Income Basic
15B 15B 1.3B 17B 15B
19 ← 15 2019 2018 2017 2016 2015
Current cash
17B 18B 18B 19B 14B
Short term investments
2B 1.6B 470M 23B 25B
14B 14B 13B 12B 11B
9B 8.6B 8.8B 8.1B 8.1B
Other current assets
2.5B 3.6B 2.5B 3.3B 3B
Current assets
45B 46B 43B 65B 60B
Long term investments
1.1B 510M 750M 1.2B 1.5B
Property plant equipment
19B 17B 17B 16B 16B
34B 30B 32B 23B 22B
Intangible assets
48B 48B 53B 27B 26B
Other assets
3.6B 3.7B 4.2B 3.2B 2.9B
Total assets
160B 150B 160B 140B 130B
Accounts payable
8.5B 7.5B 7.3B 6.9B 6.7B
Current long term debt
1.1B 2.6B 1.5B 1.7B 2.1B
Other current liabilities
24B 20B 17B 14B 13B
Total current liabilities
36B 31B 31B 26B 28B
Long term debt
27B 28B 31B 22B 13B
Other liabilities
18B 17B 17B 9.5B 10B
Minority Interest
0 0 0 0 0
Total Liabilities
98B 93B 97B 71B 62B
Common stock
2.6B 2.7B 2.7B 2.7B 2.8B
Retained earning
110B 110B 100B 110B 100B
Treasury stock
3.1M 3.1M 2.7M 2.5M 2.4M
Capital surplus
Shareholder equity
59B 60B 60B 70B 71B
Net tangible assets
-78B -67B -72B -14B -8.4B
19 ← 15 2019 2018 2017 2016 2015
Net Income
15B 15B 1.3B 17B 15B
7B 6.9B 5.6B 3.8B 3.7B
Changes in receivables
-380M -610M -1.8B -970M
Changes in inventories
-280M -640M 580M -250M -450M
Cash change
-800M 280M -1.1B 5.2B -790M
Cash flow
23B 22B 21B 19B 19B
Capital expenditures
-3.5B -3.7B -3.3B -3.2B -3.5B
-530M -1.3B 22B 1.8B -6.7B
Investing activity other
-460M -230M -120M -100M
Total investing cash flows
-6.2B -3.2B -15B -4.8B -7.7B
Dividends paid
-9.9B -9.5B -8.9B -8.6B -8.2B
Net borrowings
-2.9B -3.9B 6.8B 7.9B 1.4B
Other financing cash flows
580M -150M -190M -15M -57M
Cash flow financing
-18B -19B -7.7B -8.6B -11B
Exchange rate effect
-9M -240M 340M -220M -1.5B
Disable ads for free
Disable ads for free